Trials / Completed
CompletedNCT04628572
Retrospective Analysis of Real World Use of Ceftazidime-avibactam in the Management of Gram Negative Infections
Retrospective Analysis to Characterize the Real World Use Patterns, Efficacy and Safety of Ceftazidime-avibactam in the Management of Gram Negative Infections.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 189 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main objective of this non-interventional (retrospective) study is to describe the general treatment patterns, effectiveness, and safety of ceftazidime-avibactam in real-world settings in India. Eligible patients would be adults who have been treated with ≥ 48 hours of ceftazidime-avibactam in routine practice from 01 June 2019 to 01 April 2020. Data of 500 patients will be collected through the abstraction of hospital medical records (electronic) if available or through the individual patient medical record in case electronic records are not available.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ceftazidime-avibactam | Non-Interventional Study |
Timeline
- Start date
- 2021-01-29
- Primary completion
- 2022-03-11
- Completion
- 2022-03-11
- First posted
- 2020-11-13
- Last updated
- 2024-08-14
- Results posted
- 2024-08-14
Locations
8 sites across 1 country: India
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04628572. Inclusion in this directory is not an endorsement.